Disease Detail

ID DOID:4905
Name pancreatic carcinoma
Definition A pancreas cancer that derives_from epithelial cells located_in the pancreas.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer pancreatic carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown ABT-348 pancreatic carcinoma not applicable detail...
SMAD4 loss SD-093 pancreatic carcinoma sensitive detail...
Unknown unknown BMS-906024 pancreatic carcinoma not applicable detail...
Unknown unknown EMD 1214063 pancreatic carcinoma not applicable detail...
ERBB2 over exp HER2 CAR-T cells pancreatic carcinoma predicted - sensitive detail...
Unknown unknown Gemcitabine + MU380 pancreatic carcinoma not applicable detail...
Unknown unknown Lexatumumab + PF-573228 pancreatic carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting
NCT01537107 Phase I Sirolimus + Vismodegib Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery Completed
NCT01663272 Phase I Cabozantinib + Gemcitabine A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer Completed
NCT01954732 Phase I Metformin Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery Withdrawn
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02268825 Phase Ib/II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers Terminated
NCT02807844 Phase Ib/II MCS110 + Spartalizumab Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies Recruiting
NCT02847000 Phase 0 Decitabine + Tetrahydrouridine p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer Completed
NCT02930902 Phase I Paricalcitol + Pembrolizumab Gemcitabine + Nab-paclitaxel + Paricalcitol + Pembrolizumab Preoperative Pilot Study to Assess Safety and Immunological Effect of Pembrolizumab (Keytruda) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer Active, not recruiting
NCT02960594 Phase I INO-1400 + INO-9012 INO-1400 hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Completed
NCT03825289 Phase I Hydroxychloroquine + Trametinib Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer (THREAD) Recruiting
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Recruiting